<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583087</url>
  </required_header>
  <id_info>
    <org_study_id>20102015</org_study_id>
    <nct_id>NCT02583087</nct_id>
  </id_info>
  <brief_title>ESD for the Treatment of Early Barrett's Neoplasia</brief_title>
  <acronym>ESTEBAN</acronym>
  <official_title>Endoscopic Submucosal Dissection for the Treatment of Early Barrett's Neoplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H么pital Cochin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Society of Digestive Endoscopy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H么pital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Prive Jean Mermoz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H么pital Cochin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the quality of the resection of early neoplasia arinsing in Barrett's
      esophagus using endoscopic submucosal dissection. It is a multicenter prospective registry
      among 7 centers including all consecutive patients with early Barrett's neoplasia of 15 mm
      or more in size treated by endoscopic submucosal dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic submucosal dissection ( ESD) demonstrated great efficacy in the treatment of
      squamous cell carcinoma of the esophagus. Results for the treatment of esophageal
      adenocarcinoma arising in Barrett's esophagus are conflicting.

      In this multicenter prospective registry among 7 French centers, all consecutive patients
      with early Barrett's neoplasia of 15 mm or more in size treated by endoscopic submucosal
      dissection will be included in the registry. The primary objective is to assess the quality
      of the resection by ESD of early Barrett's neoplasia (T1A or T1B sm1 or high grade
      dysplasia). Secondary endpoints are to assess the combined efficacy of a treatment
      associating ESD and radiofrequency ablation of the remaining Barrett esophagus, and to
      assess the durability of the results after 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Rate of histologically complete (R0) resection of esophageal adenocarcinoma or high grade dysplasia</measure>
    <time_frame>3 months after ESD initial procedure</time_frame>
    <description>R0 resection rate = horizontal margins free from cancer or high grade dysplasia, and vertical margins free from carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of en bloc resection via ESD</measure>
    <time_frame>3 months after ESD initial procedure</time_frame>
    <description>presence of a single fragment of tissue on histopathological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of histologically complete (R0) resection of esophageal adenocarcinoma</measure>
    <time_frame>3 months after ESD initial procedure</time_frame>
    <description>R0 resection rate = horizontal margins free from cancer, and vertical margins free from carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of histologically complete (R0) resection of low grade dysplasia</measure>
    <time_frame>3 months after ESD initial procedure</time_frame>
    <description>R0 resection rate = horizontal margins free from cancer, high or low grade dysplasia, and vertical margins free from carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Curative resection rate of adenocarcinoma</measure>
    <time_frame>3 months after ESD initial procedure</time_frame>
    <description>R0 resection of adenocarcinoma, with submucosal invasion &lt;500micrometers, absence of poor differenciation or lymphovascular invasion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>3 months</time_frame>
    <description>early or late complications of ESD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of complete remission of adenocarcinoma, high grade dysplasia, low grade dysplasia, and intestinal metaplasia at 1 and 3 years</measure>
    <time_frame>3 years after initial procedure</time_frame>
    <description>rate of normal endoscopic and histologic follow-up after ESD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of buried glands</measure>
    <time_frame>3 years</time_frame>
    <description>Presence of Buried glands on histological analysis of follow-up biopsies</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Esophageal Neoplasm</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endoscopic submucosal dissection</intervention_name>
    <description>Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.</description>
    <other_name>endoscopic resection</other_name>
    <other_name>ESD</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18 to 90 years old with a visible lesion suspected of adenocarcinoma arising
        in a Barrett's esophagus amenable to resection by ESD.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Barrett's esophagus at least C0M2 with histological documentation of intestinal
             metaplasia

          -  Visible abnormality of at least 15 mm in size

          -  Absence of mediastinal or coeliomesenteric enlarged lymph nodes or muscle layer
             invasion on pretherapeutic EUS

          -  Absence of mediastinal or coeliomesenteric enlarged lymph nodes or metastases on
             pretherapeutic CT scan

        Exclusion Criteria:

          -  History of esophageal external irradiation

          -  History of esophagectomy or gastrectomy gastrectomie ou d'oesophagectomie

          -  Esophageal stricture

          -  Esophageal varices grade 3 or of any grade with signs of recent bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frederic Prat, MD, PhD</last_name>
    <phone>00331 58 41 19 85</phone>
    <email>frederic.prat@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maximilien Barret, Md, MSc</last_name>
    <phone>00331 58 41 19 85</phone>
    <email>maximilien.barret@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 20, 2015</lastchanged_date>
  <firstreceived_date>October 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>H么pital Cochin</investigator_affiliation>
    <investigator_full_name>Frederic PRAT</investigator_full_name>
    <investigator_title>Professor Frederic Prat</investigator_title>
  </responsible_party>
  <keyword>Barrett esophagus</keyword>
  <keyword>Esophageal adenocarcinoma</keyword>
  <keyword>Endoscopic submucosal dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
